# Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

> **NCT02974504** · PHASE4 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 207 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** evogliptin
- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT02974504
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2018-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974504, "Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02974504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*